Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS AND METHODS
Last updated:
Abstract:
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
Status:
Application
Type:
Utility
Filling date:
1 Feb 2022
Issue date:
19 May 2022